Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Cognitive Function in MS
NCT02988401Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human insulin in multiple sclerosis (MS) (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Change in Cognitive Function as Assessed by the Symbol Digit Modalities Test at 24 weeks. Started Dec 2017; status: completed.
02
Drugs
human insulin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02988401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988401.